HCDT 2.0: A Highly Confident Drug-Target Database for Experimentally Validated Genes, RNAs, and Pathways

In the process of drug treatment, drugs impact cellular actions and responses by targeting genes, RNAs, and pathways, making drug-target interactions crucial for elucidating the mechanisms of drug action and advancing drug development. At present, many drug-target-related databases exist; however, they are structurally and functionally independent, lacking consistency. In HCDT 1.0, we collected highly confident interactions between drugs and target genes. Building upon this foundation, we have developed HCDT 2.0, an updated version that incorporates drug-gene data and expands to include interactions involving drug-RNAs and drug-pathways. It involved 20 drug-related databases, standardizing drug, RNA, gene, and pathway names using consistent identifiers to ensure data consistency. In HCDT 2.0, 1,304,370 high-confidence drug-target interactions were identified, encompassing 1,244,791 interactions between 678,564 drugs and 7,297 genes, 11,770 interactions between 316 drugs and 6,430 RNAs, and 47,809 drug-pathway interactions between 6,290 drugs and 3,143 pathways. It will serve as an invaluable asset in the fields of predicting drug efficacy and adverse effects, developing novel therapeutic strategies, and facilitating the process of repurposing drugs.